Mesenchymal stem cells for the treatment of cns diseases
US-2018333458-A1 · Nov 22, 2018 · US
Isolated cells and populations comprising same for the treatment of CNS diseases
US10869899B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10869899-B2 |
| Application number | US-201715820521-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 22, 2017 |
| Priority date | Jun 16, 2005 |
| Publication date | Dec 22, 2020 |
| Grant date | Dec 22, 2020 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
An isolated human cell and populations thereof is provided comprising at least one astrocytic phenotype and at least one mesenchymal stem cell phenotype, wherein the mesenchymal stem cell phenotype is not an astrocytic phenotype.
First claim
Opening claim text (preview).
What is claimed is: 1. An isolated cell population comprising human cells which express CD90, and secrete glial derived neurotrophic factor (GDNF), wherein a secretion of said GDNF is at least 2 times greater than a basal secretion of said GDNF in non-differentiated mesenchymal stem cells, wherein the cell population is non-genetically modified, and wherein the cell population has been differentiated ex vivo from human mesenchymal stem cells. 2. The isolated cell population of claim 1 , wherein said human cells co-express said CD90 and glial fibrillary acidic protein (GFAP). 3. The isolated cell population of claim 1 , wherein a secretion of said GDNF is at least 5 times greater than a basal secretion of said neurotrophic factor in said non-differentiated mesenchymal stem cells. 4. The isolated cell population of claim 1 , wherein said human cells have a star-shaped body. 5. The isolated cell population of claim 1 , further secreting at least one neurotrophic factor selected from the group consisting of brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3), neurotrophin-4/5, Neurturin (NTN), Persephin, artemin (ART), ciliary neurotrophic factor (CNTF), insulin growth factor-I (IGF-1) and Neublastin. 6. The isolated cell population of claim 1 , wherein a secretion of said GDNF is upregulated by IL-1 beta and/or cabergoline. 7. A pharmaceutical composition comprising the isolated cell population of claim 1 . 8. A device comprising the pharmaceutical composition of claim 7 , the device being adapted for administration of the isolated cell population into the spinal cord. 9. A device comprising the pharmaceutical composition of claim 7 , the device being adapted for administration of the isolated cell population into the brain. 10. A device comprising the pharmaceutical composition of claim 7 , the device being adapted for intramuscular administration of the isolated cell population.
Assignees
Inventors
Classifications
- C12N5/0622Primary
Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells · CPC title
Epidermal growth factor [EGF] · CPC title
from bone marrow mesenchymal stem cells (BM-MSC) · CPC title
Antiepileptics; Anticonvulsants · CPC title
for peripheral neuropathies · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10869899B2 cover?
- An isolated human cell and populations thereof is provided comprising at least one astrocytic phenotype and at least one mesenchymal stem cell phenotype, wherein the mesenchymal stem cell phenotype is not an astrocytic phenotype.
- Who is the assignee on this patent?
- Univ Ramot
- What technology area does this patent fall under?
- Primary CPC classification C12N5/0622. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Dec 22 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 4 related publications on this page (citations in our corpus or others sharing the same primary CPC).